Home / Pipeline / DE-111 ophthalmic solution + Tafluprost ophthalmic solution 0.0015% + Concomitant use of tafluprost ophthalmic solution 0.0015% plus timolol ophthalmic solution 0.5% Products DE-111 ophthalmic solution + Tafluprost ophthalmic solution 0.0015% + Concomitant use of tafluprost ophthalmic solution 0.0015% plus timolol ophthalmic solution 0.5%
DE-111 ophthalmic solution + Tafluprost ophthalmic solution 0.0015% + Concomitant use of tafluprost ophthalmic solution 0.0015% plus timolol ophthalmic solution 0.5% Phase 3 Completed ⚡ Active Interest: 40/100
Open Angle Glaucoma, Ocular Hypertension
About DE-111 ophthalmic solution + Tafluprost ophthalmic solution 0.0015% + Concomitant use of tafluprost ophthalmic solution 0.0015% plus timolol ophthalmic solution 0.5% DE-111 ophthalmic solution + Tafluprost ophthalmic solution 0.0015% + Concomitant use of tafluprost ophthalmic solution 0.0015% plus timolol ophthalmic solution 0.5% is a phase 3 stage product being developed by Santen Pharmaceutical for Open Angle Glaucoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01342081. Target conditions include Open Angle Glaucoma, Ocular Hypertension.
What happened to similar drugs? 20 of 20 similar drugs in Open Angle Glaucoma were approved
Clinical Trials (1) NCT ID Phase Status Start Completion Indication NCT01342081 Phase 3 Completed May 1, 2011 — Open Angle Glaucoma
Product Company Stage Hype Score Ilofotase alfa + Placebo AM-Pharma Phase 2 Test - Bimatoprost 0.01% Ophthalmic Solution + Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution) Mankind Pharma Phase 3 Latanoprost plus adjunctive glaucoma medication Sight Sciences Approved Pirtobrutinib + Placebo Eli Lilly Phase 1/2 Anti-(integrin beta-3) human monoclonal antibody Rallybio Phase 2 SBI-100 Ophthalmic Emulsion, 0.5% + SBI-100 Ophthalmic Emulsion, 1.0% + SBI-100 Ophthalmic Emulsion, Placebo Skye Bioscience Phase 2 Micafungin Astellas Pharma Approved SDP-133 + Lumigan Sun Pharmaceutical Phase 3 Brinzolamide ophthalmic suspension + Azopt® Sun Pharmaceutical Phase 3 Placebo + Lusutrombopag Shionogi Phase 2 Lusutrombopag Shionogi Phase 2 Avatrombopag + Avatrombopag + Placebo Eisai Phase 2 E5501 Eisai Phase 1 avatrombopag Eisai Phase 1 E5501 + Drug: E5501 Eisai Phase 1 E5501 40 mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with food + E5501 40mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with food Eisai Phase 1 Eltrombopag + Avatrombopag + Standard of care Eisai Phase 3 Placebo + Avatrombopag tablets Eisai Phase 2 avatrombopag (lower baseline platelet count) + placebo (lower baseline platelet count) + avatrombopag (higher baseline platelet count) + placebo (higher baseline platelet count) Eisai Phase 3 avatrombopag + Placebo Eisai Phase 2